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Objectives
• To assess the prognostic impact of time to recurrence (TTR)
on cancer-specific survival (CSS) after recurrence in patients
with renal cell carcinoma (RCC) undergoing radical
nephrectomy or nephron-sparing surgery.
• To analyse differences in clinical and histopathological
criteria between patients with early and late recurrence.
Patients and Methods
• Of 13 107 patients with RCC from an international
multicentre database, 1712 patients developed recurrence in
the follow-up (FU), at a median (interquartile range) of 50.1
(25–106) months.
• In all, 1402 patients had recurrence at ≤5 years (Group A)
and 310 patients beyond this time (Group B).
• Differences in clinical and histopathological variables
between patients with early and late recurrence were
analysed.
• The influence of TTR and further variables on CSS
after recurrence was assessed by Cox regression
analysis.
Results
• Male gender, advanced age, tumour diameter and stage,
Fuhrman grade 3–4, lymphovascular invasion (LVI), and
pN + stage were significantly more frequent in patients with
early recurrence, who had a significantly reduced 3-year
CSS of 30% compared with patients in Group B (41%;
P = 0.001).
• Age, gender, tumour histology, pT stage, and continuous
TTR (hazard ratio 0.99, P = 0.006; monthly interval)
independently predicted CSS.
• By inclusion of dichotomised TTR in the multivariable
model, a significant influence of this variable on CSS was
present until 48 months after surgery, but not beyond this
time.
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Conclusions
• Advanced age, male gender, larger tumour diameters, LVI,
Fuhrman grade 3–4, pN + stage, and advanced tumour
stages are associated with early recurrence.
• Up to 4 years from surgery, a shorter TTR independently
predicts a reduced CSS after recurrence.
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Introduction
Surgical therapy is the only curative treatment option with a
grade-A recommendation based on current guidelines for
patients with localised RCC [1–3]. However, 20–40% of
patients will develop recurrence after surgery with curative
intent, which is associated with poor prognosis. In most
cases recurrence will develop within the first 5 years after
primary surgery; however, in 6–10% of patients recurrence
develops later (up to 45 years) in the follow-up (FU) [4–9].
Time and pattern of metastasis show strong individual
variations, and knowledge about those patients who are at
risk for recurrence at different time-points would allow for
an individualised aftercare in these patients and potentially
also for initiation of early salvage treatment after detection
of disease recurrence.
The prognostic influence of time to recurrence (TTR) on
cancer-specific survival (CSS) after disease recurrence is
controversial [10–13]. The consideration that TTR is of
prognostic relevance is provided by the Memorial
Sloan-Kettering Cancer Center (MSKCC) score for patients
with metastatic RCC, which integrates time from surgery to
metastasis with a 12-month threshold as a prognostic
parameter [12,13]. Further studies are mainly based on small
patient groups and partially suffer from inappropriate
endpoints and selection criteria or lack multivariable analysis
[10,11]. Although few prognostic models have been developed
to predict recurrence risk, significant knowledge about
differences in clinical and histopathological criteria of patients
with early and late relapse and about prognostic parameters
for CSS after recurrence is lacking [10,14–17]. As the vast
majority of publications on this topic use a 5-year threshold
for distinction of early and late recurrences, we also used
this value for analysis of differences in clinical and
histopathological criteria between patients with early and late
recurrence. Patient information was retrieved from a large
comprehensive database comprising of the multi-institutional
CORONA (Collaborative Research on Renal Neoplasms
Association) and SATURN (Surveillance and Treatment
Update Renal Neoplasms) projects including European and
American patients with RCC. Furthermore, we analysed the
prognostic impact of TTR and further variables on CSS after
recurrence.
Patients and Methods
After local Ethics Committee approval, clinical and
pathological data of 13 107 consecutive patients with
localised RCC who underwent nephron-sparing surgery
or radical nephrectomy at 23 urological departments from
Europe and the USA (period, 1992–2010) were summarised
in one database (all centres are members of the
CORONA/SATURN projects). Preoperatively, all patients
were staged M0 as described before [9]. None of the
patients received adjuvant or neoadjuvant perioperative
treatment.
The median (interquartile range, IQR) postoperative FU of
all patients was 49.5 (24–92) months. The study group
comprised 1712 patients (13.1%) who developed recurrence
within this period at a median (IQR) FU of 50.1 (25–106)
months. In all, 1402 patients (81.9%) experienced recurrence
at ≤5 years after surgery (Group A), 310 patients (18.1%,
Group B) beyond this period. Patients were followed
according to protocols according to current guideline
recommendations as described previously [9]. Recurrence
was defined as tumour relapse in the operative field, regional
lymph nodes, and/or distant metastasis. Isolated occurrence
in the contralateral kidney or in the ipsilateral kidney after
nephron-sparing surgery was not considered recurrence.
Whereas information on localisation of metastasis was
available in all patients with late recurrence, in 24.2% of
patients with early recurrence no specification of distant
metastasis was available. Duration of FU was assessed from
surgery until last FU. Death was designated as cancer-related
or not. The CSS analysed from time of recurrence to
cancer-related death was the primary endpoint of this study;
furthermore overall survival (OS) was analysed. Cause of
death was determined by treating physicians, chart review
corroborated by death certificates or death certificates alone.
To reduce bias in attribution to cause of death and to clearly
distinguish between disease-specific death and death from
other causes, only patients who had RCC listed on the
death certificate with previous disease progression were
considered to have died from cancer. Perioperative
mortality at ≤30 days of surgery was censored at the time
of death for CSS analyses. The database was frozen in
November 2011.
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Pathological assessment was performed by experienced
genitourinary pathologists at each institution. Pathological
stage was reassigned according to the 2009 American Joint
Committee on Cancer (AJCC) TNM staging system [18].
Tumour histology was assessed according to the Heidelberg
classification of renal tumours [19]. For assessment of
cell differentiation Fuhrman grade was applied [20].
Lymphovascular invasion (LVI) was defined as the presence
of tumour cells within endothelium-lined spaces without
underlying muscular walls.
The Shapiro–Wilk normality test was used to investigate
normal distribution of continuous variables. Continuous
variables are presented as median with IQRs. Pertinent
characteristics of both study groups were compared. The
Wilcoxon rank-sum (Mann–Whitney U) test was used for
variables lacking normal distribution. Comparison between
categorical variables was performed using Fisher’s exact and
chi-squares tests.
CSS and OS were estimated using the Kaplan–Meier method
as period between recurrence and cancer-related death, as
well as death from any cause, respectively; the log-rank test
was used to compare survival curves. Univariable and
multivariable Cox proportional hazards regression models
were used to assess the influence of clinical and pathological
parameters (TTR, age, gender, pathological T stage, N stage,
histological subtype, LVI, Fuhrman grade) on cancer-specific
mortality (CSM) after recurrence. Due to only incomplete
information on metastasis localisation in patients with early
recurrence, this variable was not included in multivariable
models. In all models, proportional hazards assumptions were
verified using the Grambsch-Therneau residual-based test
[21]. To account for non-linearity of TTR, Martingale residual
processes and natural log (ln) transformed hazard ratios (HRs)
were plotted and aggregated over the study group vs time as
an omnibus procedure to check the goodness-of-fit of the
multivariable model [22].
The internal model validity was evaluated by bootstrapping
based on 1000 bootstrap samples. Differences between
coefficients in the original and the bootstrap samples are
reflected by the slope (or shrinkage) index as a measure for
optimism. Normally, slope values lie between 0 and 1 with a
value of 1 indicating no optimism.
The clinical impact of dichotomised TTR on CSM in
multivariable models was assessed using the Omnibus test for
the model quality with analysis of the changing deviance (–2
multiplied log-likelihood) by means of the development of
chi-squared (percentage change of quality of a model
integrating TTR as categorical instead of continuous variable)
[23]. Furthermore, the predictive accuracy (PA) of the models
was evaluated by measures of the area-under-the-curve (AUC)
value (c-index) according to Harrell, to quantify increments of
PA associated with the addition of continuous TTR to a base
set of predictor variables, with a c-index of 1.0 indicating
perfect discrimination of patients with different outcomes
and a value of 0.5 indicating no predictive information
[24]. Comparison of the PAs was performed using the
Mantel–Haenszel test [25]. To prove adequate power of
statistical analysis, post hoc power analysis was used.
Data were analysed using R statistical package (v.2.12.2) and
SPSS 19.0 (SPSS Inc. Chicago, IL, USA). Reported P values are
two-sided with a statistical significance level of ≤0.05.
Results
Patient characteristics are shown in Table 1. The median (IQR)
FU after recurrence of patients alive at the study end was 14
(3–37) months. Patients developing recurrence at ≤5 years
from surgery (Group A) were significantly older than patients
in group B (64.1 vs 61.8 years, P = 0.002), more often men
(64.6% vs 58.4%, P = 0.043), and had larger tumours at
primary diagnosis (7 vs 6 cm, P < 0.001). Significantly more
frequent LVI (41.5% vs 29%, P < 0.001), Fuhrman grade 3–4
(52% vs 27.4%, P < 0.001), pN + stage (7.1% vs 1%, P < 0.001),
and advanced tumour stages (≥pT3: 56.2 vs 43.5%, P < 0.001)
were found in patients with early recurrence, whereas
distribution of histological subtypes did not significantly differ
between both groups. Patients with early and late recurrence,
respectively, mainly developed simultaneous recurrence at
multiple localisations (37.1% vs 54.1%, respectively). In those
patients with recurrence at single organ sites, localisations
varied widely in all patients (Table 2).
CSS rates for the entire study group calculated from time of
recurrence at 6, 12, 24, 36, and 60 months were 74%, 59%,
43%, 32%, and 23%, respectively. Kaplan–Meier analysis
showed significantly different 3-year CSS rates for Group A
and B patients with 30% and 41% (P < 0.001), respectively. By
further distinguishing patients with early recurrence based on
a TTR of ≤12 months and >12–60 months, CSS rates after 3
years were 24% and 35%, respectively (P < 0.001, Fig. 1).
In univariable analyses, age, gender, tumour histology and size,
pT stage, LVI, Fuhrman grade and continuous TTR, as well
as TTR up to an interval of 108 months influenced CSS
(Table 3). Based on multivariable analysis of the complete
study group, age, gender, tumour histology, pT stage, and
continuous TTR (HR 0.99, P = 0.006; monthly interval) were
independently associated with CSM, whereas LVI, Fuhrman
grade, and pN status had no significant influence (Table 4).
Our study confirmed TTR as an independent prognostic
parameter until 48 months after primary surgery based on
evaluation of several categorical thresholds (from 12 to 120
months), which were applied in separate multivariable models
(Table 4). The relative risk of dying from cancer in patients
who had recurrence beyond these thresholds was 0.79–0.84
(P ≤ 0.012) compared with patients with recurrence before
each of these thresholds; the best model quality was provided
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by the 12-month threshold (Table 4). If recurrence occurred
>4 years after surgery, it was no longer associated with
significantly reduced CSS (Table 4). Stratification of patients
according to a TTR of <12 months, 12–48 months, and >48
months provided significantly different CSS rates and is shown
in Fig. 2. Accordant Kaplan–Meier curves for OS related to
both stratifications are displayed in Figs S3 and S4,
respectively, each showing significantly different survival rates
as well.
Table 1 Characteristics of 1712 patients with RCC (all of them M0 at time of surgery) with recurrence after surgery by time of recurrence.
Characteristic Overall Group A
Recurrence ≤5 years
Group B
Recurrence >5 years
P
Number of patients 1712 1402 310
Median (IQR):
Age at surgery, years 63.9 (55.9–70.0) 64.1 (56.0–70.8) 61.8 (55.3–68.1) 0.002
Tumour size, cm 7.0 (5.0–9.5) 7.0 (5.0–10.0) 6.0 (4.5–8.0) <0.001
N (%):
Female gender 625 (36.5) 496 (35.4) 129 (41.6) 0.043
Partial nephrectomy 280 (16.4) 228 (16.3) 52 (16.8) 0.800
ccRCC 1437 (83.9) 1178 (84.0) 259 (83.5) 0.864
LVI* 521 (38.6) 431 (41.5) 90 (29.0) <0.001
Fuhrman grade 3–4 814 (47.5) 729 (52.0) 85 (27.4) <0.001
pT stage (2009) <0.001
pT1a 236 (13.8) 183 (13.1) 53 (17.1)
pT1b 308 (18.0) 234 (16.7) 74 (23.9)
pT2a 167 (9.8) 132 (9.4) 35 (11.3)
pT2b 77 (4.5) 64 (4.6) 13 (4.2)
pT3a 536 (31.3) 450 (32.1) 86 (27.7)
pT3b 289 (16.9) 240 (17.1) 49 (15.8)
pT3c 27 (1.6) 27 (1.9) 0
pT4 72 (4.2) 72 (5.1) 0
pN stage (2009) <0.001
pN0/pNx 1610 (94.0) 1303 (92.9) 307 (99.0)
pN+ 102 (6.0) 99 (7.1) 3 (1.0)
Median (IQR):
FU after surgery, months 50.1 (25–106) 36.6 (21–61) 130.6 (104–155) <0.001
FU after recurrence, months 14.0 (3–37) 13 (4–35) 19.8 (3–41) 0.105
ccRCC, clear cell RCC; *Information on LVI was only available in 1348 patients.
Table 2 Localisations of recurrence in patients with early and late
recurrence.
Site of recurrence Group A Group B
Early recurrence Late recurrence
Number of patients 1402 310
N (%):
Local recurrence only 21 (1.5) 16 (5.2)
Multiple localisations 759 (54.1) 115 (37.1)
Solitary metastasis 283 (20.2) 179 (57.7)
Lung/thorax 122 (8.7) 84 (27.1)
Bone 52 (3.7) 28 (9.0)
Brain 32 (2.3) 17 (5.5)
Lymph nodes 34 (2.4) 15 (4.8)
Abdomen 17 (1.2) 12 (3.9)
Pancreas 0 6 (1.9)
Liver 12 (0.9) 6 (1.9)
Thyroid gland 2 (0.1) 5 (1.6)
Adrenal gland 10 (0.7) 3 (1.0)
Dermis 3 (0.2) 3 (1.0)
Distant metastasis with not
specified localisation
339 (24.2) 0
Table 3 Results of univariable analyses of several clinical and
histopathological parameters for CSM after recurrence.
Factors HR (95% CI) P
Age at surgery, continuous 1.02 (1.01–1.03) <0.001
Female gender (reference: male) 0.78 (0.69–0.89) <0.001
Partial nephrectomy (reference: radical
nephrectomy)
0.66 (0.55–0.79) <0.001
Clear cell RCC (reference: non-clear cell RCC) 0.83 (0.70–0.98) 0.027
Tumour size, continuous 1.04 (1.02–1.05) <0.001
LVI present (reference: LVI absent)* 1.34 (1.19–1.52) <0.001
Fuhrman grade 3–4 (reference: Fuhrman grade 1–2) 1.23 (1.09–1.38) 0.001
pT stage (8 stages) 1.12 (1.08–1.15) <0.001
Positive nodes (reference: pN0/pNx) 1.38 (1.09–1.74) 0.007
TTR, continuous (in months) 0.99 (0.99–0.99) <0.001
TTR ≤12 months 1 Reference
TTR >12 – ≤60 months 0.73 (0.64–0.83) <0.001
TTR >60 months 0.80 (0.73–0.87) <0.001
TTR >12 months (reference: ≤12 months) 0.71 (0.62–0.80) <0.001
TTR >24 months (reference: ≤24 months) 0.75 (0.66–0.84) <0.001
TTR >36 months (reference: ≤36 months) 0.74 (0.65–0.84) <0.001
TTR >48 months (reference: ≤48 months) 0.73 (0.63–0.84) <0.001
TTR >60 months (reference: ≤60 months) 0.75 (0.64–0.89) 0.001
TTR >72 months (reference: ≤72 months) 0.73 (0.61–0.88) 0.001
TTR >84 months (reference: ≤84 months) 0.72 (0.58–0.89) 0.003
TTR >96 months (reference: ≤96 months) 0.73 (0.58–0.93) 0.010
TTR >108 months (reference: ≤108 months) 0.75 (0.57–0.98) 0.038
TTR >120 months (reference: ≤120 months) 0.73 (0.53–1.01) 0.060
*Information on LVI was only available in 1348 patients.
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The regression coefficients of these models were corrected for
optimism by multiplying the original coefficients by the
shrinkage factor (slope indices: 0.96–0.98). The PA of the
multivariable model including information on continuous
TTR in comparison with a model without integration of this
variable were 62.2% (95%CI 59.5–65) and 61.7% (95%CI
59–64.5), respectively, which was not significantly different
(PA gain 0.5%, P = 0.112). However, based on the Omnibus
1.0
0.8
0.6
0.4
0.2
0.0
C
SS
0 24 48 72 96 120
Months after recurrence
P < 0.001
≤ 12 months
12−60 months
>60 months
Number of patients at risk /  
Number of cumulative events  
0 
months  
24  
months  
48  
months
72  
months  
96  
months  
12 0 
months  
Recurrence within 12 months 596/0 126/350  59/387  33/401  21 /406  15/409  
Recurrence after 12 to 60 months 806/0 254/355 111/444  64/475  34/494 13 /501  
Recurrence after 60 months 310/0 108/117  46/150  20/159  8/162  2/164  
Fig. 1 CSS after disease recurrence by risk
stratification related to TTR (≤12, >12–60, >60
months).
Table 4 Results of separate multivariable Cox regression analyses with inclusion of clinical and histopathological parameters for CSM after recurrence.
Factor HR (95% CI) P Improvement of model
quality†, % (reference 100%)
Age at surgery, continuous 1.02 (1.01–1.03) <0.001
Female gender (reference: male) 0.78 (0.68–0.89) <0.001
Clear cell RCC (reference: non-clear cell) 0.82 (0.70–0.98) 0.026
LVI present (reference: LVI absent)# 1.01 (0.86–1.19) 0.866
Fuhrman grade 3–4 (reference: Fuhrman grade 1–2) 1.10 (0.97–1.25) 0.125
pT stage (8 stages) 1.10 (1.06–1.15) <0.001
Positive nodes (reference: pN0/pNx) 1.08 (0.85–1.38) 0.541
TTR, continuous (in months) 0.99 (0.99–0.99) 0.006
Results of separate multivariable models each with inclusion of one threshold value for TTR instead of continuous
TTR together with all other parameters according to the original model
TTR (≤12, >12–60, >60 months)* 0.85 (0.78–0.93) <0.001 +3.74
TTR >12 months (referent: ≤12 months) * 0.79 (0.69–0.89) <0.001 +5.52
TTR >24 months (referent: ≤24 months)* 0.84 (0.74–0.95) 0.006 +1.06
TTR >36 months (referent: ≤36 months)* 0.84 (0.73–0.96) 0.009 −0.01
TTR >48 months (referent: ≤48 months)* 0.83 (0.71–0.96) 0.012 −0.72
TTR >60 months (referent: ≤60 months)* 0.87 (0.73–1.02) 0.094 −3.39
TTR >72 months (referent: ≤72 months)* 0.85 (0.70–1.03) 0.094 −3.54
TTR >84 months (referent: ≤84 months)* 0.82 (0.66–1.02) 0.076 −3.29
TTR >96 months (referent: ≤96 months)* 0.85 (0.67–1.08) 0.192 −4.37
TTR >108 months (referent: ≤108 months)* 0.90 (0.68–1.18) 0.437 −5.15
TTR >120 months (referent: ≤120 months)* 0.90(0.64–1.25) 0.528 −5.25
#Information on LVI was only available in 1348 patients; *P values, HRs, and 95% CI refer to separate multivariable models in which either continuous TTR or one different threshold
value for TTR was analysed together with all other parameters; †improvement of the model quality refers to the multivariable model with inclusion of continuous TTR as reference
(100%).
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test, integration of TTR as a three-categorical (≤12, >12–60,
>60 months) and dichotomized variable (≤12, >12 months),
respectively, resulted in a robust improvement of the model
quality by 3.7% and 5.5%, respectively (each P < 0.001),
compared with a model with continuous inclusion (Table 4).
Based on statistical power analysis, differences within the
significance level (α err probability <0.05) could be
determined for a small effect size (0.2) with a power of 96.2%.
Discussion
Based on previous reports, about one-third of patients with
localised RCC will develop disease recurrence after primary
surgery with curative intent [1–9,15]. Effective surveillance
protocols should allow individually tailored aftercare based on
parameters predicting recurrence and possibly also time of
recurrence. Few protocols have been developed to stratify
patients according to their individual risk of recurrence in
general and at different time-points mainly based on the TNM
system, grading, and tumour necrosis [15–17]. Furthermore,
TTR was also assessed as prognostic parameter hinting at
early recurrence ≤12 months as a predictor of reduced
survival [10–13]. However, information was received from
study cohorts of primary M1 patients only or small patient
cohorts undergoing surgery, sometimes lacking multivariable
analysis or using inappropriate endpoints, so that reliable
information about the exact influence of TTR on CSS after
recurrence is still lacking.
The present study provides enhanced information on this
topic based on the most comprehensive multicentre database
published to date including >13 000 patients with initially
localised RCC. Furthermore, it represents the first analysis of
the predictive value of several threshold values of TTR for
CSS after recurrence.
The results of the present study prove several statements. First,
we could define tumour stage and histological subtype as
criteria assessed at primary surgery as well as gender and age
as independent prognostic parameters for CSS after detection
of recurrence. Interestingly, neither Fuhrman grade nor LVI
and pN stage significantly influenced CSS in this context.
Secondly, the results prove a short period between primary
surgery and recurrence as an indicator for reduced CSS after
recurrence, which supports previously published data.
Rodriguez-Covarrubias et al. [10] found that TTR had an
independent influence on CSS; however, based on only 66
patients with recurrence and related to overall CSS but not on
CSS after recurrence. Eggener et al. [11] also reported TTR to
be predictive for OS in 118 patients with recurrent disease,
multivariable analysis, however, was lacking. Also Leibovich
et al. [26] reported that recurrence ≤2 years after primary
surgery was associated with reduced CSS based on a study
cohort of patients with metastatic RCC. Based on the present
data, the usually applied threshold of 5 years could be
challenged in favour of 48 months for distinction of early and
late recurrences, as up to this time prognosis of patients was
P < 0.001
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Number of patients at risk /
Number of cumulative events
0 
months  
24  
months  
48  
months  
72  
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96  
months  
120  
months  
Recurrence within 12 months 596/0  126/350  59/387  33/401  21/406  15/409  
Recurrence after 12 to 48 months 694/0  203/311  86/385  51/409  26/425  12/428  
Recurrence after 48 months 422/0  159/161  71/209  33/225  16/231  3/237  
Fig. 2 CSS after disease recurrence by risk
stratification related to TTR (≤12, >12–48, >48
months).
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reduced with every day that recurrence occurred earlier, but
not beyond a threshold of 48 months.When looking at the
baseline parameters with significant differences in prevalence
between patients with early and late recurrences based on the
5-year threshold, these parameters still showed significantly
different frequencies in the two resulting patient groups when
the 48-month threshold was applied (data not shown).
Stratification of patients according to a TTR of <12 months,
12–48 months, and >48 months provided significantly different
CSS, as well as OS rates. Yet, beside a significant improvement
of the model quality, an integration of continuous TTR in the
multivariable model only resulted in a marginal improvement
of the PA of this stable multivariable model.
As mentioned above, we detected significantly different
distributions of some criteria in patients with early and late
tumour recurrence regardless of using the 60-month or the
48-month threshold for definition of late recurrence. Beside
tumour size, LVI, Fuhrman Grade, pT and pN stage, also older
and male patients were significantly more prevalent in cases of
early recurrence. These results are concordant with the results
published by Adamy et al. [17], who found that late recurrence
in 44 patients was associated with smaller tumour size and less
aggressive disease at first presentation.
The robustness of the present data is furthermore
corroborated by considering lead-time bias occurring in
recurrence diagnosis.While early recurrence regularly will be
detected earlier in asymptomatic patients, as aftercare is
provided at shorter intervals, late recurrence will be detected
later, as regular aftercare is normally not provided anymore
after >5 years. In the present study, patients with late
recurrence survived longer despite this lead-time bias, which
confirms the significance and reliability of the present data.
A further interesting point is that, despite an adequately long
FU, only 12% of patients in the present study group developed
recurrence in contrast to previous published data with
recurrence rates of 20–40%, which might indicate a generally
improved prognosis for patients with RCC today. This might
be based on improvements in surgical treatment or on
increasing detection of tumours at earlier stages with less risk
of recurrence after surgery.
Despite being based on the largest database reported to date
on this topic, with inclusion of a many patients with recurrent
disease than reported before, the present study has all the
limitations inherent in retrospective and multicentre
evaluations, e.g. missing standardisation of diagnosis, therapy,
and aftercare, as well as possible limitations in quality of
data assessment and the risk of unmeasured confounding.
Information on symptoms and treatment in cases of
recurrence, concomitant comorbidities, and further laboratory
parameters, which are for example included in the MSKCC
score (such as haemoglobin or calcium), were not available for
all patients and, hence, not analysed. Information on LVI was
also not available for all patients included. Furthermore,
central pathological review was not performed, as this would
have gone beyond the scope of a study group comprised of
>13 000 patients. For a fraction of patients with early
recurrence, localisation of distant metastasis was not available
and thus not analysed. In addition, beside standard clinical
and histopathological parameters, molecular markers should
also ideally be incorporated into multivariable models in
future studies, which was not performed in the present as well
as in all other studies regarding this issue. Besides, with a
median FU of 50.1 month a potential era effect resulting in
marginally altered patient group composition and slight
disparities between patients with early and late recurrences
has to be considered as a potential confounder, which might
also lead to subtly nuanced HRs. However, based on the
distribution of recurrences in the database and anticipated
recurrences in the course of disease, during this median FU
nearly 77% of recurrences have already occurred, which limits
the potential risk of bias.
In conclusion, besides age, gender, tumour histology, and pT
stage, TTR is a significant predictor of CSS after recurrence in
patients with RCC who undergo primary surgery with curative
intent. The earlier after surgery recurrence occurs, the more
reduced is survival after recurrence. Vice versa, the prognosis
of patients with recurrent disease is improved with every day a
patient stays disease-free after surgery up to 4 years from
surgery, but not beyond this time. Advanced age, male gender,
advanced tumour diameter and stage, LVI, Fuhrman grade
3–4, and pN + stage were more frequent in patients with early
recurrence, which might provide the possibility of risk adapted
aftercare. Furthermore, these data may also be useful for
implementation as an important stratification tool in clinical
trials to avoid bias, e.g. to allow for equal representation of
early and late recurrence patients in treatment arms.
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